This segment focuses on developing and commercializing a range of molecular diagnostic tests, primarily in women's health and reproductive health. Key products include non-invasive prenatal screening (NIPS) tests like Innatal, which screens for chromosomal abnormalities such as Down syndrome, and carrier screening tests like Preparent, which identifies carrier status for hereditary diseases. The segment also offers Resura, a NIPT for single-gene disorders, and Preecludia, a preeclampsia rule-out test. R&D efforts are directed towards improving the accuracy and expanding the scope of these tests, incorporating advanced genomic technologies and bioinformatics. The goal is to provide clinicians and patients with actionable information for informed decision-making, improving pregnancy outcomes and family planning.

This segment is dedicated to the development of novel therapeutic solutions for gastrointestinal (GI) disorders. The pipeline includes PGN-001, PGN-300, PGN-600, and PGN-OB2, which are designed to address various GI-related conditions. Research and development activities focus on targeted drug delivery systems and ingestible technologies to improve drug efficacy and patient compliance. The segment leverages advanced materials science and microfabrication techniques to create innovative drug delivery devices. The aim is to provide targeted therapies that reduce systemic side effects and improve the quality of life for patients suffering from chronic GI conditions such as inflammatory bowel disease (IBD).